Nichole Tucker

Following impressive data presented at the ASH Annual Meeting, the FDA granted approval to olutasidenib or the treatment of patients with treatment-naïve and relapsed or refractory acute myeloid leukemia.

Phase 3 study findings have led to the FDA approval of nadofaragene firadenovec-vncg for a subgroup of patients with high-risk Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer.

Early results from the TROPION-PanTumor01 demonstrate the potential of achieving durable response with datopotamab deruxtecan while maintaining tolerability in patients with hormone receptor-positive or HER2-negative breast cancer.

An extended progression-free survival and 54% reduction in the risk of death was shown with high-dose chemotherapy autologous stem cell transplantation consolidation therapy vs non-myeloablative chemoimmunotherapy in patients with primary central nervous system lymphoma.

Results from MonumenTAL-1 presented during the 2022 ASH annual Meeting have led to the submission of a biologics license application for talquetamab.

Compared with standard of care regimens for triple-class exposed, relapsed or refractory multiple myeloma, belantamb mafodotin with pomalidomide and dexamethasone extended progression-free survival without sacrificing safety.

In an interview with Targeted Oncology, Tapan M. Kadia, MD, discussed e-selection inhibition, and other novel targets for acute myeloid leukemia therapy.

Yielding a 46% reduction in the risk of disease progression of death compared with combination chemotherapy, ribociclib plus endocrine therapy may be a new standard of care for patients with pre/perimenopausal HR-positive, HER2-negative advanced breast cancer

In patients with PSMA-positive metastatic castration-resistant prostate cancer, the PSMA-directed therapy with 177Lu-PSMA-617, led to significant improvement in radiographic progression-free survival.

The FDA will conduct a regular review of the application submitted for approval of I/ONTAK in patients with persistent or recurrent cutaneous T-cell lymphoma.

The phase 2 RUBY clinical trial has met its primary end point with dostarlimab-gxly given after chemotherapy achieving progression-free survival improvement in adult patients with primary advanced or recurrent endometrial cancer.

The FDA has granted a fast track designation to the combination of pelareorep and atezolizumab with gemcitabine and nab-paclitaxel for advanced or metastatic pancreatic ductal adenocarcinoma after promising results were presented from the GOBLET study at the SITC Annual Meeting.

Positive and durable complete responses observed with olutasidenib in adult patient with relapsed or refractory acute myeloid leukemia and a susceptible IDH1 mutation have led the FDA to grant approval to the drug for this group of patients

On the heels of a negative ODAC vote, poziotinib has was not approved by the FDA on it PDUFA date, and the developer of poziotinib will stop development immediately.

Results from the phase 3 KEYNOTE-859 study show extended overall and progression-free survival in patients with HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal adenocarcinoma treated with pembrolizumab and chemotherapy.

In an interview with Targeted Oncology, Michael T. Tees, MD, discussed the donor-derived CAR T-cell product, ALLO-501A, and research supporting the agent.

Based on positive findings from the phase 2 pivotal EPCORE NHL-1, the FDA will conduct a speedy review of the biologics license application for subcutaneous epcoritamab for the treatment of patients with relapsed/refractory large B-cell lymphoma after 2 or more lines of systemic therapy an granted it priority review.

In an interview with Targeted Oncology, Megan R. Haymart, MD, provided a recap of a symposium at the American Thyroid 2022 Annual Meeting and discussed disparities in thyroid cancer care, as well as potential solutions

Real-world evidence from Florida Cancer Specialists & Research Institute shows that trilaciclib may reduce the chance of chemotherapy-induced myelosuppression events in patients with extensive-stage small cell lung cancer.

Initial results from the phase 3 spotlight study show that the study met its primary and key secondary end point of progression-free and overall survival.

In season 3, episode 10 of Targeted Talks, Nitika Sharma, MD, discusses FDA-approved and promising novel therapies for the treatment of small cell lung cancer.

In an interview with Targeted Oncology, Michael Chuong, MD, discussed how 5 fractions of ablative radiation therapy compare with 15-25 fractions for the treatment of locally advanced pancreatic cancer.

In an interview with Targeted Oncology, Ryan J. Sullivan, MD, discussed the history of tumor infiltrating lymphocyte therapy, how new data may lead to approved agents in the future, and other ways tumor infiltrating lymphocytes may be used in advanced melanoma.

With the addition of eganelisib to atezolizumab plus nab-paclitaxel, patients with metastatic triple negative breast cancer have longer progression-free survival and better response vs atezolizumab and nab-paclitaxel alone.

The impressive POSEIDON clinical trial results have led to the FDA approval of tremelimumab in combination with durvalumab and platinum-based chemotherapy for the treatment of metastatic non–small cell lung cancer.

The FDA has advised ADC Therapeutics that a randomized phase 3 confirmatory study is needed to support a future FDA approval for camidanlumab tesirine as treatment of relapsed or refractory Hodgkin lymphoma.

Ipsen plans to seek FDA approval for the NALIRIFOX regimen based on positive results from the phase 3 NAPOLI 3 clinical trial.

Results from bemarituzumab in the phase 2 FIGHT study hint that FGFR2b may be a new target of interest in gastric cancer.

Positive Study 16113 results have led the FDA to grant approval to to cemiplimab in combination with chemotherapy for the treatment of patients with advanced non–small cell lung cancer.

Retrospective real-world evidence shows that patients who relapse after B-cell maturation antigen chimeric antigen receptor T-cell therapy may have multiple treatment options, including salvage therapy and T-cell engagers.